CS
COGT icon

Candriam SCA’s Cogent Biosciences COGT Stock Holding History

Candriam SCA’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$80.7M Buy
2,088,369
+572,072
+38% +$20M 0.36% 55
2026
Q1 		$58.4M Buy
1,516,297
+219,822
+17% +$8.12M 0.3% 74
2025
Q4 		$46.1M Buy
1,296,475
+342,266
+36% +$9.62M 0.23% 97
2025
Q3 		$13.7M Buy
954,209
+526,867
+123% +$6.24M 0.07% 225
2025
Q2 		$3.07M Buy
+427,342
New +$2.37M 0.02% 429
2024
Q1 		– Sell
-232,487
Closed -$1.37M – 703
2023
Q4 		$1.37M Sell
232,487
-545,000
-70% -$4.18M 0.01% 542
2023
Q3 		$7.53M Buy
777,487
+5,000
+0.6% +$59.3K 0.05% 261
2023
Q2 		$9.15M Sell
772,487
-164,654
-18% -$1.89M 0.07% 256
2023
Q1 		$9.31M Sell
937,141
-60,000
-6% -$767K 0.06% 267
2022
Q4 		$11.5M Sell
997,141
-154,361
-13% -$1.91M 0.08% 244
2022
Q3 		$17.2M Sell
1,151,502
-99,387
-8% -$1.36M 0.12% 182
2022
Q2 		$11.3M Sell
1,250,889
-502,091
-29% -$3.43M 0.09% 209
2022
Q1 		$13.1M Sell
1,752,980
-112,792
-6% -$785K 0.09% 216
2021
Q4 		$16M Sell
1,865,772
-61,477
-3% -$534K 0.1% 203
2021
Q3 		$16.2M Buy
1,927,249
+16,529
+0.9% +$127K 0.11% 204
2021
Q2 		$15.5M Buy
1,910,720
+1,435,911
+302% +$12.1M 0.11% 224
2021
Q1 		$5.12M Buy
474,809
+79
+0% +$761 0.04% 369
2020
Q4 		$5.33M Buy
+474,730
New +$5.22M 0.04% 378

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Candriam SCA's COGT Position: Q2 2026 in Review

Candriam SCA increased its Cogent Biosciences (COGT) stake by 38% in Q2 2026, buying an estimated $20M and bringing the position to 2,088,369 shares worth $80.7M. The position accounts for 0.36% of the portfolio, ranked #55.

Candriam SCA first reported a position in COGT in Q4 2020 and has held it in 18 quarters since. 324 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

  • Candriam SCA held 2,088,369 shares of Cogent Biosciences worth $80.7M as of Q2 2026.
  • Candriam SCA bought 572,072 Cogent Biosciences shares in Q2 2026, an estimated $20M.
  • Cogent Biosciences made up 0.36% of Candriam SCA's portfolio in Q2 2026, its #55 holding.
  • Candriam SCA first reported a position in Cogent Biosciences in Q4 2020 and has held it in 18 quarters since.
  • 324 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on Candriam SCA's 13F filing for Q2 2026, filed 13 Aug 2026.